DUBLIN, January 27, 2015 \/PRNewswire\/ -- <\/p>\n
Research and Markets (http:\/\/www.researchandmarkets.com\/research\/pfd99m\/recombinant<\/a>) has announced the addition of the \"Recombinant Coagulation Factors 2015: Maturation Of Recombinant Clotting Factor Pipeline And Emergence Of Gene Therapy And Alternative Procoagulants\" report to their offering. (Logo: http:\/\/photos.prnewswire.com\/prnh\/20130307\/600769<\/a> ) <\/p>\n A Pipeline Landscape Analysis and Comparative Assessment of Key Players <\/p>\n This report provides an update of recombinant coagulation factors used for controlling bleeding of hemophilia A and B and other bleeding disorders. 2013 sales figures and 2014 nine-month sales data are analyzed to evaluate commercial development of the market under the light of a strong pipeline and entry of new competitor products into the market. The profiles of drug candidates in development are presented in details not only for recombinant coagulation factors VIII, IX and VII, but also for emerging alternative procoagulants, gene therapeutics and immune tolerance inducing agents. <\/p>\n The competitve landscape of classical recombinant coagulation factors and of new emerging treatment modalities of hemophilia and other severe bleeding orders is analyzed. The emergence of new treatment modalities brings many new stakeholders to the field of hemophilia. Among them are the established hemophilia portofolio companies, but also new entrants from Big Pharma and Big Biotech, specialty pharmaceutical companies, biosimilar companies, and new technology providers as half-life prolongation technologies are no longer in the focus of major interest. <\/p>\n A short- to mid-term outlook into the field is provided and the trends driving the future of this therapeutic segment are identified and described. Preparation of this report is based on information stored in La Merie Publishing's proprietary data base and news archive, on scientific literature, and on corporate disclosures. The data are presented, analyzed and assessed in a comprehensive manner by an experienced author with an independent view writing the fifth edition of this report series. <\/p>\n Key Topics Covered: <\/p>\n 1. Executive Summary <\/p>\n 2. Recombinant Coagulation Factor Markets 2.1 Recombinant Factor VIII (rFVIII) Product Sales and Market Size 2.2 Recombinant Factor IX (rFIX) Product Sales and Market Size 2.3 Recombinant Factor VII (rFVII) Product Sales and Market Size 2.4 Recombinant Thrombin Product Sales and Market Size 2.5 Total Recombinant Coagulation Factor Market Size <\/p>\n 3. Pipeline Update of Recombinant Coagulation Factors 3.1 Factor VIII Pipeline Changes and Drug Profile Updates 3.2 Factor IX Pipeline Changes and Drug Profile Updates 3.3 Factor VII Pipeline Changes and Drug Profile Updates 3.4 Pipeline Update for Other Recombinant Coagulation Factors 3.5 Pipeline Update for Alternative Procoagulants 3.6 Pipeline Update for Gene & Cell Therapy 3.7 Immune Tolerance Inducing (ITI) Agents <\/p>\n <\/p>\n View original post here: <\/p>\n Recombinant Coagulation Factors 2015: Maturation Of Recombinant Clotting Factor Pipeline And Emergence Of Gene Therapy ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" DUBLIN, January 27, 2015 \/PRNewswire\/ -- Research and Markets (http:\/\/www.researchandmarkets.com\/research\/pfd99m\/recombinant<\/a>) has announced the addition of the \"Recombinant Coagulation Factors 2015: Maturation Of Recombinant Clotting Factor Pipeline And Emergence Of Gene Therapy And Alternative Procoagulants\" report to their offering. (Logo: http:\/\/photos.prnewswire.com\/prnh\/20130307\/600769<\/a> ) A Pipeline Landscape Analysis and Comparative Assessment of Key Players This report provides an update of recombinant coagulation factors used for controlling bleeding of hemophilia A and B and other bleeding disorders. Continue reading